Anna Dalgaard

CHAIRPERSON

On the board since 2016. Master of Business Administration from the Stockholm School of Economics, and also studied medicine at Karolinska Institutet. Experience: Anna has extensive experience in the healthcare industry, having worked as a McKinsey & Company consultant in the healthcare sector, as the Head of business development at Colonix Medical and as a project director at Scandinavian Health Partner. She is also a co-founder of healthcare companies Health Navigator AB and Aktiv Hälsostyrning i Sverige AB (now Lumell Associates AB). Anna is currently serving as a board member of Add Health Media AB, Ortivus AB (publ), Arthro Therapeutics AB, and ADDI Medical AB. Independent in relation to the Company and the Group management. Independent in relation to the Company’s major shareholders. Anna Dalgaard owns 19,000 warrants and 13,000 shares in Hemcheck. Dalgaard also indirectly controls 20,000 shares in Hemcheck.

Jenni Björnulfson

MEMBER

On the board since 2016. Bachelor of Business Administration from Stockholm School of Economics, having also studied at Karolinska Institutet. Experience: Jenni has extensive experience from the financial market, as she worked with corporate finance for ten years at Handelsbanken Markets and at Alfred Berg Fondkommission/ABN AMRO, and for three years as an equity analyst at Standard & Poor's and ABG Sundal Collier. She was as a business area manager at Global Health Partner and is currently the CFO and IR manager of Promore Pharma. In addition, Jenni is a board member of The C Story AB. Independent in relation to the Company and the Group management. Independent in relation to the Company’s major shareholders. Jenni Björnulfsson owns 19,000 warrants and 5,000 shares in Hemcheck.

Hjalmar Didrikson

MEMBER

On the board since 2010, and chaired the board between 2010 and 2015. Bachelor of Business Administration from Stockholm School of Economics. Hjalmar is a co-founder of Hemcheck, and of investment company Alfvén & Didrikson AB. He has broad international experience from the investment business: he has worked as a Senior Director at EQT (Stockholm and Warsaw) and previously also at FSN Capital Partners (Oslo) and UBS Investment Bank (London). Independent in relation to the Company and the Group management. Independent in relation to the Company’s major shareholders. Hjalmar Didrikson owns 121,830 shares in Hemcheck. He also indirectly controls 80,300 shares via Karlsson foundation and 1,256,325 shares as a co-owner of Stockholm Karlstad Invest.

Torbjörn Koivisto

MEMBER

On the board since 2016. Master of Laws from Uppsala University. Experience: Torbjörn is a business lawyer focusing on corporate and commercial law. He previously worked for Mannheimer Swartling, Lindahl and Bird & Bird. Since 2006, he runs a legal consultancy firm, IARU Affärsjuridisk Rådgivning i Uppsala AB, and his experience also includes several years as a consultant to companies in the life science sector. Torbjörn is currently a board member of XSpray Pharma AB (Publ), Cinclus Pharma Holding AB and KIBACQ AB. Independent in relation to the Company and the Group management. Independent in relation to the Company’s major shareholders. Torbjörn Koivisto owns 19,000 warrants and 8,000 shares in Hemcheck.

Karin Dahllöf

MEMBER

On the board since 2018. Biomedical analyst. Karin has more than 27 years of experience from management, marketing and sales in international medtech companies such as HemoCue AB, CellaVision AB, Bonesupport AB, Chromogenix AB in Sweden; EKF Diagnostics Ltd. in the UK; and Vida Care B.V. in the Netherlands. She is currently the acting CEO of Monivent AB, and a board member of Boule Diagnostics AB. Independent in relation to the Company and the Group management. Independent in relation to the Company’s major shareholders. Karin Dahllöf owns 30,415 shares in Hemcheck.

Måns Alfvén

ALTERNATE MEMBER

Alternate member since 2015. Bachelor of Business Administration from Stockholm School of Economics. Experience: Måns has served many years as a consultant at The Boston Consulting Group, including as a project manager. He has also worked as a trade commissioner for the Swedish Trade Council in Australia and as the CEO of Eirus Medical AB. A co-founder of investment company Alfvén & Didrikson, Måns has extensive experience from boards, among others with Trustly Group AB and Quinyx AB. Independent in relation to the Company and the Group management. Independent in relation to the Company’s major shareholders. Måns Alfvén owns 5,000 shares in Hemcheck. He indirectly controls 1,256,325 shares as a co-owner of Stockholm Karlstad Invest.